Sutro Biopharma Inc (STRO) Reports Q3 2023 Financial Results and Business Updates
-
Sutro Biopharma Inc (NASDAQ:STRO) released its 8-K filing on November 13, 2023, detailing third-quarter financials and recent business highlights.
-
The company reported a cash and investment balance of $321.1 million, projecting a cash runway into the first half of 2025.
-
Revenue for Q3 2023 stood at $16.9 million, a decrease from $25.1 million in the same period in 2022.
-
Sutro's total operating expenses were $60.9 million for the quarter, with research and development expenses accounting for $45.7 million.
On November 13, 2023, Sutro Biopharma Inc (NASDAQ:STRO) announced its financial results for the third quarter of 2023, along with key business highlights and anticipated milestones. The company, known for its innovative approach to antibody drug conjugates (ADCs), has shown a strong financial position with $321.1 million in cash and investments, and an additional $34.0 million in Vaxcyte common stock, ensuring a cash runway into the first half of 2025.
Business Highlights and Anticipated Milestones
Sutro's recent months have been marked by significant progress, particularly with its lead candidate, luvelta, showing promising preliminary anti-tumor activity in endometrial cancer. The company also welcomed Dr. Hans-Peter Gerber as the new Chief Scientific Officer, bringing extensive experience in ADCs to the team. Sutro's Phase 2/3 trial for luvelta in platinum-resistant ovarian cancer is progressing well, with global enrollment underway.
Luvelta is also being evaluated in other indications, including a compassionate use program for a rare form of acute myeloid leukemia (AML), with updated data to be presented at ASH 2023. Additionally, Sutro is preparing for IND applications for other pipeline candidates, including STRO-003 and STRO-004, targeting ROR1 and tissue factor, respectively.
Financial Performance
For the third quarter of 2023, Sutro reported revenues of $16.9 million, a decrease from $25.1 million in the same quarter of the previous year. This decline was primarily related to the Astellas collaboration and the recognition of a contingent payment from Tasly. Operating expenses increased to $60.9 million, up from $46.4 million in Q3 2022, with research and development expenses constituting the bulk of the costs.
The company also highlighted a non-operating, unrealized gain of $0.7 million from the increase in the value of its Vaxcyte common stock holdings. Sutro's royalty monetization agreement with Blackstone Life Sciences brought in a $140 million upfront payment, with the potential for an additional $250 million in future milestone payments.